Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

AVTX holding history

Avalo Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AVTX overviewAll 13F holders of AVTXFull Q2 2026 holdings

Shares (Q2 2026)
128,075
Value
$2.37M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of AVTX by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026128,075$2.37M<0.1%−33,317−20.6%ReducedHolders
Q1 2026161,392$2.41M<0.1%−103,515−39.1%ReducedHolders
Q4 2025264,907$4.81M<0.1%+264,897+2,648,970.0%AddedHolders
Q3 202510$127<0.1%00.0%UnchangedHolders
Q2 202510$50<0.1%−350−97.2%ReducedHolders
Q1 2025360$2.88K<0.1%+350+3,500.0%AddedHolders
Q4 202410$74<0.1%00.0%UnchangedHolders
Q3 202410$96<0.1%00.0%UnchangedHolders
Q2 202410$124<0.1%−29−74.4%ReducedHolders
Q1 202439$848<0.1%−5−11.4%ReducedHolders
Q4 202344$400<0.1%−10,470−99.6%ReducedHolders
Q3 202310,514$1.27K<0.1%−309−2.9%ReducedHolders
Q2 202310,823$3.85K<0.1%−1,503−12.2%ReducedHolders
Q1 202312,326$21.6K<0.1%−99−0.8%ReducedHolders
Q4 202212,425$62.6K<0.1%+826+7.1%AddedHolders
Q3 202211,599$38.0K<0.1%+8,228+244.1%AddedConverted for a 1-for-12 splitHolders
Q2 202240,450$20.0K<0.1%−34,865−46.3%ReducedHolders
Q1 202275,315$54.0K<0.1%−79,142−51.2%ReducedHolders
Q4 2021154,457$262.0K<0.1%+80,632+109.2%AddedHolders
Q3 202173,825$160.0K<0.1%−122,854−62.5%ReducedHolders
Q2 2021196,679$643.0K<0.1%+195,487+16,399.9%AddedHolders
Q1 20211,192$3.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.